Interindividual Variation in the Pharmacokinetics of Δ9‐Tetrahydrocannabinol as Related to Genetic Polymorphisms in  CYP2C9 | Zendy

SachseSeeboth C | Zendy; Pfeil J | Zendy; Sehrt D | Zendy; Meineke I | Zendy; Tzvetkov M | Zendy; Bruns E | Zendy; Poser W | Zendy; Vormfelde SV | Zendy; Brockmöller J | Zendy

Premium

Interindividual Variation in the Pharmacokinetics of Δ9‐Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

Author(s) -

SachseSeeboth C,

Pfeil J,

Sehrt D,

Meineke I,

Tzvetkov M,

Bruns E,

Poser W,

Vormfelde SV,

Brockmöller J

Publication year - 2009

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2008.213

Subject(s) - cyp2c9 , pharmacokinetics , pharmacology , clinical pharmacology , tetrahydrocannabinol , pharmacogenetics , medicine , sedation , delta 9 tetrahydrocannabinol , genotype , biology , cannabinoid , genetics , gene , cytochrome p450 , receptor , metabolism

The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9‐tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11‐nor‐9‐carboxy‐9‐tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC. Clinical Pharmacology & Therapeutics (2009); 85 , 3, 273–276 doi: 10.1038/clpt.2008.213

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research